

November 7, 2025

News Release

Company: Olympus Corporation

Bob White, Director, Representative Executive Officer, President and CEO

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-42-642-2111

Notice: Concerning Change of Representative Executive Officer and Executive Officer

Olympus Corporation ("Olympus") hereby announces that at the Board of Directors Meeting held today, it was tentatively decided to change the executive officers as described below. It is scheduled to be decided formally by the Board of Directors in March 2026 and to take effect on April 1, 2026.

1. Reason for change of Representative Executive Officer

Yasuo Takeuchi was appointed the Representative Director and President on April 1, 2019, as the leader driving the transformation plan “Transform Olympus” announced on January 11, 2019. Since then, he streamlined our business portfolio, diversified our Executive Team and Board of Directors, and laid the foundation for Olympus to become a truly Global MedTech company. Thanks to these efforts, we are now entering the next phase of growth. With the completion of our new corporate strategy announced today, Yasuo Takeuchi has made the decision to confidently pass the baton to the next generation of leadership.

2. Reason for change of Executive Officer

Frank joined Olympus in 1993, since then, he made significant contributions to Olympus in mainly endoscopic business, and regional and global managerial roles. In addition, he led and invested our entry into endoluminal robotics and the endoscopy ecosystem in order to grow our Gastrointestinal Solutions business in the future.

The successor, Keith Boettiger joined Olympus on April 1, 2025, as Gastrointestinal Solutions Division Head, and has extensive knowledge and broad experience in sales, research and development, and regulatory affairs. Since then, he has played a pivotal role in major projects and has also been instrumental in leading organizational development and transformative initiatives to create new business growth opportunities.

Keith will continue to drive the growth strategy and innovation for the Gastrointestinal Solutions Division with strong and effective leadership from April 2026.

3. Names and job titles of newly appointed and retiring executive officer

(1) Newly appointed executive officer

Name	Current job titles	New job titles after April 1, 2026
Keith Boettiger	Executive Vice President and Gastrointestinal Solutions Division Head	Executive Officer and Gastrointestinal Solutions Division Head

(2) Departure executive officer

Name	Current job titles	New job titles after April 1, 2026
Yasuo Takeuchi	Director, Representative Executive Officer, Executive Chairperson and ESG Officer	Non-executive Director
Frank Drewalowski	Executive Officer and Gastrointestinal Solutions	Senior advisor to CEO

4. Career summary of newly appointed executive officer

Keith Boettiger

Date of Birth:	February 22, 1970	
Career summary:	January 1999	Full-line Senior Sales Territory Manager, Johnson & Johnson
	March 2004	Territory Manager, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	April 2006	Regional Sales Director, Mid-Atlantic Region, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	June 2008	Vice President, Western Area Sales, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	January 2010	Vice President US Sales, Neuromodulation Division, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	January 2013	Division Vice President, Chronic Pain Therapies, Neuromodulation, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	June 2014	Senior Vice President & General Manager, Chronic Pain and Movement Disorder Therapies, St. Jude Medical, Inc. (acquired by Abbott Laboratories)
	January 2017	Division Vice President, Abbott Neuromodulation, Abbott Laboratories
	July 2017	Vice President Abbott & President Abbott Neuromodulation Division, Abbott Laboratories
	October 2021	Vice President Abbott & President Abbott Heart Failure Division, Abbott Laboratories

	April 2025	Joined Olympus Corporation of the Americas Corporate Officer, Gastrointestinal Solutions Division Co-Head, Olympus Corporation
	April 2026	Executive Officer and Gastrointestinal Solutions Division Head, Olympus Corporation (plan)
Number of shares of the Company held (Note) (Of which, the number of shares to be delivered under the stock compensation plan):		141,843 (141,843)

(Note) “Number of shares of the Company held” indicates the number of shares held as of September 30, 2025. It also includes the number of shares each candidate holds through the Employees’ Shareholding Association of the Company, his/her own equity interest held through a company managing stock compensation of the Company as well as the number of shares to be delivered under the stock compensation plan.